<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153709</url>
  </required_header>
  <id_info>
    <org_study_id>17-0471</org_study_id>
    <secondary_id>1R01HD088279-01A1</secondary_id>
    <secondary_id>UNCPM-21701</secondary_id>
    <nct_id>NCT03153709</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Evaluating Pregnancy Rates, PK Interactions Among HIV+ Women on EFV Initiating LNG Implant or DMPA</brief_title>
  <acronym>FP-ART</acronym>
  <official_title>A Prospective Cohort Evaluating the Pregnancy Rates and Pharmacokinetic Interactions Among HIV-infected Malawian Women on Efavirenz Initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pregnancy rates among women who are using the HIV
      drug Efavirenz and either the birth control injection or implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective 1: To compare the typical-use pregnancy rates of 710 HIV+ DMPA-users on EFV with
      710 HIV+ LNG implant users on EFV through a prospective observational cohort.

      The investigators will enroll 710 HIV-infected women on EFV who are initiating the LNG
      implant and 710 HIV-infected women on EFV who are initiating the DMPA injectable and follow
      them 1 month after contraceptive initiation and then every 6 months until the end of the
      4-year study time period. The investigators will recruit and enroll over a period of 2 years;
      those who are enrolled at the beginning of the enrollment period may complete up to 4 years
      of follow-up, whereas those who are enrolled at the end of the 2-year enrollment period will
      complete 2 years of follow-up. Women will have urine, blood, and hair specimens obtained at
      each study visit. The primary outcome will be incident pregnancy, evaluated by urine
      pregnancy testing. The secondary outcome will be contraceptive continuation, evaluated by
      palpation (for LNG implant) and review of the woman's medical record and study forms (for
      DMPA). A marginal structural Poisson model will be used to estimate the effect of implant
      compared to DMPA upon pregnancy incidence. The investigators will adjust for key potential
      confounders, including frequency of intercourse, age, and body mass index (BMI).

      Objective 2: To assess whether greater EFV exposure (measured by hair concentrations) is
      associated with contraceptive failure in LNG implant users in a 2:1 nested case-control study
      of 240 LNG implant users.

      The investigators estimate that a maximum of 120 pregnancies will occur among LNG implant
      users in the cohort in Objective 1. From this cohort, the investigators will compare 80
      pregnant women who were using the LNG implant at the time of conception and 160 controls who
      had intercourse during the previous 3 months and were not pregnant after a similar period of
      LNG implant use. A conditional logistic regression model will be used to assess the
      association between EFV hair concentrations and contraceptive failure; key potential
      confounders the investigators will adjust for in the analysis include frequency of
      intercourse, age, weight, and length of time on EFV. The data for this Objective's exposure,
      outcome, and confounders will be derived from the Data Collection Forms and study specimens
      obtained in Objective 1.

      Objective 3: To evaluate the effect of EFV 400 mg daily on LNG concentrations among a subset
      of 25 women enrolled in the prospective cohort study who initiated the LNG implant.

      The investigators plan to enroll 25 of the 710 EFV users from their prospective cohort in
      Objective 1 who are initiating the LNG implant into the pharmacokinetic sub-study. All 25 of
      these women will be enrolled from 1 health facility, Area 18 Health Centre, and all women
      will be taking EFV 400 mg daily, which is the standard dose that Malawi will be implementing
      this year due to its equivalent efficacy but decreased cost and side effects when compared to
      EFV 600 mg daily. Follow-up visits for women in the sub-study will be conducted at 4, 12, 24,
      36, and 48 weeks post-implant initiation. Since these women would already be attending visits
      at 4, 24, and 48 weeks post-implant initiation, there will only be 2 extra study visits for
      these sub-study participants at 12 weeks post-implant initiation (Visit 1a) and 36 weeks
      post-implant initiation (Visit 2a). During the extra Visits 1a and 2a, urine, blood, and hair
      specimens will be obtained so that pregnancy testing can be performed and blood and hair can
      be stored for VL, EFV, and LNG testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rates of 710 HIV+ DMPA-users on EFV</measure>
    <time_frame>4 years</time_frame>
    <description>urine pregnancy testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pregnancy rates of 710 HIV+ LNG implant users on EFV</measure>
    <time_frame>4 years</time_frame>
    <description>urine pregnancy testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFV concentration from blood</measure>
    <time_frame>4 years</time_frame>
    <description>A validated HPLC-UV assay for EFV will be used for plasma analysis. Concentrations of EFV in a range of 10 to 10,000 ng/mL will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFV concentration from hair</measure>
    <time_frame>4 years</time_frame>
    <description>Using an IR-MALDESI imaging source coupled to a Thermo Q-Exactive/H-ESI II Bundle mass spectrometer, ~1 cm samples of hair, which will give resultant band intensities over the hair will be analyzed. EFV concentrations at each band intensity will be quantified based on a standard curve.64 Both the total and average concentrations over the 6-month period will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The LNG concentrations from serum</measure>
    <time_frame>4 years</time_frame>
    <description>The sensitivity of the LNG is 0.05 ng/ml, and the intraassay and interassay coefficients of variation (CVs) are 4.4% and 8.9%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV viral load from plasma</measure>
    <time_frame>4 years</time_frame>
    <description>HIV RNA in the range of 40-10,000,000 copies/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA quantitated from whole blood</measure>
    <time_frame>4 years</time_frame>
    <description>Using a Qiagen DNA extraction kit for blood, 1uL of whole blood will be processed to obtain DNA. This DNA will be quantitated and 120ng will be used in the assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>contraceptive continuation</measure>
    <time_frame>4 years</time_frame>
    <description>palpation (for LNG implant) and review of the woman's medical record and study forms (for DMPA).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1420</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        710 HIV-infected women on EFV who are initiating the LNG implant and 710 HIV-infected women
        on EFV who are initiating the DMPA injectable
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-40 years

          2. Documented HIV-infected status

          3. Current use of EFV

          4. Fluency in English or Chichewa (the most commonly-spoken language in Malawi)

          5. Not currently pregnant (to be confirmed by urine pregnancy test)

          6. Initiation of DMPA or the LNG implant within the past 28 days (to be confirmed by
             verification in the woman's Health Passport and palpation of the implant if
             applicable)

          7. No use of their current contraceptive during the 3 months before they recently
             initiated it (i.e., they must be newly starting and not just continuing their chosen
             contraceptive)

          8. No desire for pregnancy in the next 4 years

          9. Most recent HIV VL &lt;1,000 copies/mL (as per Malawi guidelines, women who have VL
             â‰¥1,000 copies/mL will need to be referred for possible 2nd-line ART without EFV)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Tang, MD, MSRC</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-CH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Tang, MD, MSCR</last_name>
    <phone>+265-99-640-2662</phone>
    <email>jennifer_tang@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC Project</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy rates</keyword>
  <keyword>pharmacokinetic interactions</keyword>
  <keyword>Women on efavirenz</keyword>
  <keyword>initiating the Levonorgestrel Implant</keyword>
  <keyword>initiating the Depot Medroxyprogesterone Acetate Injectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

